Skip to main content
SpringerLink
Log in

Optimizing Drug Prescribing in Managed Care Populations

Improving Clinical and Economic Outcomes

  • Review Article
  • Published:
Disease Management & Health Outcomes

Abstract

Managed care presents interesting opportunities to optimize clinical and economic outcomes related to drug prescribing. There are very few randomized controlled trials that have evaluated methods to educate or incentivize physicians, implement formulary management or guideline tools, profile physicians, and implement pharmacist interventions to ensure optimal drug prescribing. Single methods of optimizing medication outcomes have not been shown to be as effective as multifaceted approaches. Specific reinforcement of the message at the time of prescribing has been shown to improve antibiotic prescribing in patients with chronic bronchitis and improve adherence to treatment guidelines for the management of patients following myocardial infarction. Results from a randomized controlled trial showed that changes in pharmacy benefit design decreased costs and medication utilization. Much of the literature evaluating the effectiveness of utilization management techniques in optimizing drug therapy outcomes is retrospective in nature. However, pharmacist intervention has been shown to reduce polypharmacy in a randomized controlled trial in the elderly. Appropriate prescribing scores were improved and this improvement was sustained at 12 months post intervention.

Clinical pharmacy services have been shown to reduce hospital admission and hospital days, decrease prescription and total health care costs, reduce the number of drugs per patient, and improve attainment of target low density lipoprotein cholesterol values.

Recent analyses have shown that there is a higher likelihood of achieving improved outcomes of care when three or more of the following aspects of healthcare are impacted: patient self-management, clinical information availability, redesign of the way care is delivered, decision support strategies, the healthcare system, and the provider organization. In a review of interventions designed to improve the care of patients with chronic illnesses, process variables were improved when one or two of the aspects were improved. Outcome variables were improved when three or four of the aspects were impacted.

There continues to be great focus on improving the quality of care in managed care environments. With the passing of the Medicare legislation in the US, by 2006 the vast majority of citizens will receive healthcare in managed care environments. Additional research designed to explore methods of optimizing drug therapy outcomes is needed to characterize the most efficient, transparent, and least costly ways to reduce misuse, overuse, and underuse of prescription drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Fig. 1
Table V

Similar content being viewed by others

References

  1. Centers for Medicare and Medicaid Services. 2003 CMS statistics 8014623597: US Department of Health and Human Services [online]. Available from URL: http://www.cms.hhs.gov/researchers/pubs/03cmsstats.pdf [Accessed 2004 Jan 31]

  2. Centers for Medicare and Medicaid Services. Healthcare spending reaches $1.6 trillion in 2002 [online]. Available from URL: http://www.cms.hhs.gov/media/press/release.asp?.counter=935> [Accessed 2003 Oct 14]

  3. Mehrotra A, Bodenheimer T, Dudley RA. Employers’ efforts to measure and improve hospital quality: determinants of success. Health Aff 2003 Mar/Apr; 22(2): 60–71

    Article  Google Scholar 

  4. Board on Health Care Services. Fostering rapid advances in healthcare: learning from system demonstrations. Washington, DC: The National Academies Press, 2002

    Google Scholar 

  5. Adams K, Corrigan JM, editors. Priority areas for national action: transforming health care quality. Washington, DC: National Academy Press, 2003

    Google Scholar 

  6. Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human: building a safer health system. Washington, DC: National Academy Press, 1999

    Google Scholar 

  7. Institute of Medicine. Crossing the quality chasm: a new health system for the twenty-first century. Washington, DC: National Academy Press, 2001

    Google Scholar 

  8. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990 Mar; 47(3): 533–43

    PubMed  CAS  Google Scholar 

  9. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001 Mar/Apr; 41(2): 192–9

    CAS  Google Scholar 

  10. National Committee for Quality Assurance. The Health Plan Employer Data and Information Set (HEDIS®) [online]. Available from URL: http://www.ncqa.org/Programs/HEDIS/index.htm [Accessed 2003 Oct 14]

  11. National Business Coalition on Health. eValue 8 [online]. Available at: http://www.nbch.org/documents/evalue8brochure.pdf [Accessed 2004 Mar 8]

  12. Fairman KA. The effect of new and continuing prescription drug use on cost: a longitudinal analysis of chronic and seasonal utilization. Clin Ther 2000 May; 22(5): 641–52

    Article  PubMed  CAS  Google Scholar 

  13. Beers MH, Baran RW, Frenia K. Drugs and the elderly: part 1. The problems facing managed care. Am J Manag Care 2000 Dec; 6(12): 1313–20

    PubMed  CAS  Google Scholar 

  14. Finkelstein JA, Lozano P, Farber HJ, et al. Underuse of controller medications among Medicaid-insured children with asthma. Arch Pediatr Adolesc Med 2002 Jun; 156(6): 562–7

    PubMed  Google Scholar 

  15. Rautakorpi UM, Lumio J, Huovinen P, et al. Indication-based use of antimicrobials in Finnish primary health care: description of a method for data collection and results of its application. Scand J Prim Health Care 1999 Jun; 17(2): 93–9

    Article  PubMed  CAS  Google Scholar 

  16. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000 Oct; 25(5): 333–40

    Article  PubMed  CAS  Google Scholar 

  17. Gonzales R, Steiner JF, Lum A, et al. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA 1999 Apr 28; 281(16): 1512–9

    Article  PubMed  CAS  Google Scholar 

  18. Zarowitz BJ, Stebelsky L, Gillanders F, et al. Improving medication safety through the reduction of polypharmacy in a large capitated population [abstract]. Pharmacotherapy 2003; 23: 1349

    Google Scholar 

  19. Andrade SE, Gurwitz JH, Fish LS. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. Med Care 1999 Apr; 37(4): 424–30

    Article  PubMed  CAS  Google Scholar 

  20. Brufsky JW, Ross-Degnan D, Calabrese D, et al. Shifting physician prescribing to a preferred histamine-2-receptor antagonist: effects of a multifactorial intervention in a mixed-model health maintenance organization. Med Care 1998 Mar; 36(3): 321–32

    Article  PubMed  CAS  Google Scholar 

  21. Bloome M, Bronken T, Saier R, et al. Telehealth attainment of lipid goals through automated workflow technology [abstract]. Pharmacotherapy 2000 Oct; 20(10): 1259

    Google Scholar 

  22. Smits H, Zarowitz B, Sahney VK, et al. The business case for pharmaceutical management: a case study. Field report #613. 2003 Apr. [online]. Available from URL: http://www.cmwf.org/programs/quality/smits_pharmaceuti-calmanagement_613.pdf [Accessed 2003 Oct 14]

  23. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland: Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997 Aug 14; 337(7): 441–6

    Article  PubMed  CAS  Google Scholar 

  24. Miller M, Byington R, Hunninghake D, et al. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada: prospective randomized evaluation of the vascular effects of Norvasc trial (PREVENT) investigators. Arch Intern Med 2000; 160(3): 343–7

    Article  PubMed  CAS  Google Scholar 

  25. Levit K, Smith C, Cowan C, et al. Trends in US health care spending, 2001. Health Aff 2003 Jan/Feb; 22(1): 154–64

    Article  Google Scholar 

  26. National Institute for Health Care Management Research and Educational Foundation. Prescription drug expenditures in 2001: another year of escalating costs: 2002 May [online]. Available from URL: http://www.nihcm.org/spend-ing2001.pdf [Accessed 2003 Oct 14]

  27. US Department of Health and Human Services Administration on Aging. A profile of older Americans: 2002 [online]. Available from URL: http://www.aoa.gov/prof/Statistics/statistics.asp [Accessed 2003 Mar 29]

  28. Altman S, Parks-Thomas C. Controlling spending for prescription drugs. N Engl J Med 2002 Mar 14; 346(11): 855–6

    Article  PubMed  Google Scholar 

  29. Calabretta N. Consumer-driven, patient-centered health care in the age of electronic information. J Med Libr Assoc 2002 Jan; 90(1): 32–7

    PubMed  Google Scholar 

  30. Hollander SM. Providing health information to the general public: a survey of current practices in academic health sciences libraries. Bull Med Libr Assoc 2000 Jan; 88(1): 62–9

    PubMed  CAS  Google Scholar 

  31. Angel JE. Advertising drags. New York Times 2002 Jun 8; Sect. A: 14 (col. 4)

  32. Rosenthal MB, Berndt ER. Promotion of prescription drugs to consumers. N Engl J Med 2002 Feb 14; 346(7): 498–505

    Article  PubMed  Google Scholar 

  33. Mintzes B. Direct to consumer advertising is medicalising normal human experience. BMJ 2002 Apr 13; 347(7342): 908–9

    Article  Google Scholar 

  34. Mintzes B, Barer M. Influence of direct to consumer pharmaceutical advertising and patient’s requests on prescribing decisions: two site cross sectional survey. BMJ 2002 Feb 2; 321: 278–9

    Article  Google Scholar 

  35. Reichert S, Todd S, Halm E. Physicians’ attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med 2000 Oct 9; 160(18): 2799–803

    Article  PubMed  CAS  Google Scholar 

  36. Rochon P, Gurwitz J. Optimizing drag treatment for elderly people: the prescribing cascade. BMJ 1997 Oct 25; 315(7115): 1096–9

    Article  PubMed  CAS  Google Scholar 

  37. Johnson J, Bootman L. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995 Oct 9; 155(18): 1949–56

    Article  PubMed  CAS  Google Scholar 

  38. Honigman B, Lee J, Rothschild J, et al. Using computerized data to identify adverse drag events in outpatients. J Am Med Inform Assoc 2001; 8: 254–66

    Article  PubMed  CAS  Google Scholar 

  39. Senst BL, Achusism LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drag events in a health care network. Am J Health-Syst Pharm 2001; 58(12): 1126–32

    PubMed  CAS  Google Scholar 

  40. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drag reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–5

    Article  PubMed  CAS  Google Scholar 

  41. Zhan C, Sangl J, Bierman A, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 medical expenditure panel survey. JAMA 2001 Dec 12; 286(22): 2823–9

    Article  PubMed  CAS  Google Scholar 

  42. Joyce GF, Escarce JJ, Solomon MD, et al. Employer drag benefit plans and spending on prescription drugs. JAMA 2002 Oct 9; 288(14): 1733–9

    Article  PubMed  Google Scholar 

  43. Ernst M, Kelly M, Hoens J. Prescription medication costs: a study of physician familiarity. Arch Fam Med 2000 Nov–Dec; 9(10): 1002–7

    Article  PubMed  CAS  Google Scholar 

  44. Giaquinta D, Lehman G, Miller R. A managed care stakeholder assessment of preventive medicine: practical applications, measurable results, evaluating success. J Manage Care Pharm 2002 Jul–Aug; 8(4 Suppl.): 1–10

    Google Scholar 

  45. Groves K, Flanagan PS, MacKinnon N, et al. Why physicians start or stop prescribing a drug: literature review and formulary implications. Formulary 2002 Apr; 37: 186–94

    Google Scholar 

  46. Remington T. The pharmacist-prescriber interface. In: Mueller BA, Bertch KE, Zarowitz BJ, et al., editors. Pharmacotherapy self-assessment program. 4th ed. Kansas City (MO): American College of Clinical Pharmacy, 2001: 61–83

    Google Scholar 

  47. Butler C, Rollnick S, Stott N. The practitioner, the patient and resistance to change: recent ideas on compliance. CMAJ 1996 May 1; 154(9): 1357–62

    PubMed  CAS  Google Scholar 

  48. Majumdar SR, Soumerai SB. Why most interventions to improve physician prescribing do not seem to work. CMAJ 2003 Jul; 169(1): 30–1

    PubMed  Google Scholar 

  49. American Medical Association. Ethical opinions and guidelines. E-8.061 Gifts to physicians from industry [online]. Available from URL: http://www.ama-assn.org/ama/pub/print/article/4001-7922.html [Accessed 2003 Oct 14]

  50. Pharmaceutical Researchers and Manufacturers of America. PhRMA Code on interactions with healthcare professionals [online]. Available from URL: http://www.phrma.org/publications/policy//2002-04-19.391.pdf [Accessed 2003 Sep 7]

  51. Bodenheimer T. Disease management in the American market. BMJ 2000 Feb 26; 320(7234): 563–6

    Article  PubMed  CAS  Google Scholar 

  52. Navarro RP, Christensen D, Leider H. Disease management programs. In: Navarro RP, editor. Managed care pharmacy practice. Gaithersburg (MD): Aspen Publishers, 1999: 371–95

    Google Scholar 

  53. Bodenheimer T. Disease management: promises and pitfalls. N Engl J Med 1999 Apr 15; 340(15): 1202–5

    Article  PubMed  CAS  Google Scholar 

  54. Hunter DJ, Fairfield G. Disease management. BMJ 1997 Jul 5; 315(7099): 50–3

    Article  PubMed  CAS  Google Scholar 

  55. Harris JM. Disease management: new wine in new bottles? Ann Intern Med 1996 May 1; 124(9): 838–42

    PubMed  Google Scholar 

  56. Bodenheimer T. Primary care in the United States: innovations in primary care in the United States. BMJ 2003 Apr 12; 326(7393): 796–8

    Article  PubMed  Google Scholar 

  57. Bodenheimer T, Wagner EH, Grambach K. Improving primary care for patients with chronic illness. JAMA 2002 Oct 9; 288(14): 1775–9

    Article  PubMed  Google Scholar 

  58. Academy of Managed Care Pharmacy. Principles of a sound drag formulary system [online]. Available from URL: http://www.amcp.org/publications/in-dex_publications.asp [Accessed 2003 May 3]

  59. Joyce GF, Escarce JJ, Solomon DP, et al. Employer drag benefit plans and spending on prescription drags. JAMA 2002 Oct 9; 288(14): 1733–9

    Article  PubMed  Google Scholar 

  60. Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions? Am J Manag Care 2002 Dec; 8(12): 1041–54

    PubMed  Google Scholar 

  61. Nair KV, Ganther JM, McCollynm MM, et al. Impact of multi-tiered pharmacy benefits on attitudes of plan members with chronic disease states. J Manag Care Pharm 2002 Nov/Dec; 8(6): 477–91

    PubMed  Google Scholar 

  62. Motheral B, Fairman KA. Effect of three-tier prescription copay on pharmaceutical and other medical utilization. Med Care 2001 Dec; 39(12): 1293–304

    Article  PubMed  CAS  Google Scholar 

  63. Balas E, Boren S, Brown GD, et al. Effect of physician profiling on utilization: meta-analysis of randomized clinical trials. J Gen Intern Med 1996 Oct; 10(11): 584–90

    Article  Google Scholar 

  64. Levine S, Campen D, Millarees M, et al. Kaiser Permanente’s prescription drag benefit. Health Aff 2000 Mar–Apr; 19(2): 185–90

    Article  CAS  Google Scholar 

  65. Glasgow RE, Funnell MM, Bonomi AE. Self-management aspects of the improving the chronic illness care breakthrough series: implementation with diabetes and heart failure teams. Ann Behav Med 2002 Spring; 24(2): 80–7

    Article  PubMed  Google Scholar 

  66. Bodenheimer T, Lorig K, Holman H, et al. Patient self-management of chronic diseases in primary care. JAMA 2002 Nov 20; 288(19): 2469–75

    Article  PubMed  Google Scholar 

  67. Candy PC. Preventing “information overdose”: developing information-literate practitioners. J Contin Educ Health Prof 2000 Fall; 20(4): 228–37

    Article  PubMed  CAS  Google Scholar 

  68. Tierney W. Improving clinical decisions and outcomes with information: a review. Int J Med Inf 2001 Jun; 62(1): 1–9

    Article  CAS  Google Scholar 

  69. Haynes RB, Hayward R, Lomas J. Bridges between health care research evidence and clinical practice. J Am Med Inform Assoc 1995 Nov–Dec; 2(6): 342–50

    Article  PubMed  CAS  Google Scholar 

  70. O’Connor PJ, Amundson G, Christianson J. Performance failure of an evidencebased upper respiratory infection clinical guideline. J Fam Pract 1999 Sep; 48(9): 690–7

    PubMed  Google Scholar 

  71. Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow practice guidelines? A framework for improvement. JAMA 1999 Oct; 282(15): 1458–65

    Article  PubMed  CAS  Google Scholar 

  72. Soumerai SB, McLaughlin TJ, Gurwitz JH, et al. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA 1998 May; 279(17): 1358–63

    Article  PubMed  CAS  Google Scholar 

  73. Davis D, Thomson M, Oxman AD, et al. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA 1995 Sep 6; 274(9): 700–5

    Article  PubMed  CAS  Google Scholar 

  74. Van Eijk M, Avorn J, Porsius AJ, et al. Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing. BMJ 2001 Mar 17; (322): 1–5

    Article  Google Scholar 

  75. Headrick LA, Speroff T, Pelecanos HI, et al. Efforts to improve compliance with the national cholesterol education program guidelines: results of a randomized controlled trial. Arch Intern Med 1992 Dec; 152(12): 2490–6

    Article  PubMed  CAS  Google Scholar 

  76. Browner WS, Baron RB, Solkowitz S, et al. Physician management of hypercholesterolemia: a randomized trial of continuing medical education. West J Med 1994 Dec; 161(6): 572–8

    PubMed  CAS  Google Scholar 

  77. Hagen N, Young J, MacDonald N. Diffusion of standards of care for cancer pain. CMAJ 1995 Apr; 152(8): 1205–9

    PubMed  CAS  Google Scholar 

  78. Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134: 600–20

    PubMed  CAS  Google Scholar 

  79. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy and pervention. Am J Respir Crit Care Med 2001; 163: 1730–54

    Google Scholar 

  80. Sinus and Allergy Health Partnership. Antimicrobial guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2000; 123: 5–31

    Article  Google Scholar 

  81. Bisno AL, Gerber MA, Gwaltney Jr JM, et al. Practice guidelines for the diagnosis and management of Group A streptococcal pharyngitis: Infectious Diseases Society of America. Clin Infect Dis 2002; 35: 113–25

    Article  PubMed  Google Scholar 

  82. Hanlon J, Weinberger M, Samsa G, et al. A randomized, controlled trial of a clinical pharmacist’s intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996 Apr; 100(4): 428–37

    Article  PubMed  CAS  Google Scholar 

  83. Borgsdorf L, Miano J, Knapp K. Pharmacist-managed medication review in a managed care system. Am J Hosp Pharm 1994 Mar 15; 51(6): 772–7

    PubMed  CAS  Google Scholar 

  84. Devoe J, Phil M, Fryer G, et al. Does career dissatisfaction affect the ability of family physicians to deliver high-quality patient care? J Fam Pract 2002 Mar; 51(3): 223–8

    PubMed  Google Scholar 

  85. Shortell S, Waters T, Clarke K, et al. Physicians as double agents: maintaining trust in an era of multiple accountabilities. JAMA Sep 23/30; 280 (12): 1102–8

  86. Grol R. Improving the quality of medical care: building bridges among professional pride, payer profit, and patient satisfaction. JAMA 2001 Nov 28; 286(20): 2578–85

    Article  PubMed  CAS  Google Scholar 

  87. Holmes-Rovner M, Valade D, Orlowski C, et al. Implementing shared decisionmaking in routine practice: barriers and opportunities. Health Expect 2000 Sep; 3(3): 182–91

    Article  PubMed  Google Scholar 

  88. Baines D, Whynes D, Tolley K. General practitioner fundholding and prescribing expenditure control, evidence from a rural english health authority. Pharmacoeconomics 1997 Apr; 11(4): 350–8

    Article  PubMed  CAS  Google Scholar 

  89. McGavock H. Strategies to improve the cost effectiveness of general practitioner prescribing: an international perspective. Pharmacoeconomics 1997 Sep; 12(3): 307–11

    Article  PubMed  CAS  Google Scholar 

  90. Milstein C, Venot A. Cost-related information to be provided by computerised drug-prescription systems to promote cost-effective prescribing. Pharmacoeconomics 1997 Aug 12; 2 (Pt 1): 130–9

    Article  Google Scholar 

  91. Bloor K, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors. BMJ 1996 Jun 15; 312(7045): 1525–7

    Article  PubMed  CAS  Google Scholar 

  92. De Vault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94(6): 1434–42

    Article  Google Scholar 

  93. Bates DW, Teich J, Lee D, et al. The impact of computerized physician order on medication error prevention. J Am Med Inform Assoc 1999; 6(4): 313–21

    Article  PubMed  CAS  Google Scholar 

  94. Ponedal S, Tucker M. Understanding decision support systems. J Managed Care Pharm 2002 Mar–Apr; 8(2): 96–101

    Google Scholar 

  95. Monane M, Matthias D, Nagle B, et al. Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking the physician, pharmacist, and computer. JAMA 1998 Oct 14; 280(14): 1249–52

    Article  PubMed  CAS  Google Scholar 

  96. Bieszk N, Patel R, Heaberlin A, et al. Detection of mediation nonadherence through review of pharmacy claims data. Am J Health Syst Pharm 2003 Feb 15; 60(4): 360–6

    PubMed  Google Scholar 

  97. Bieszk N, Bhargava V, Petitta T, et al. Quality and cost outcomes of a clinical pharmacist intervention in a capitated senior drug benefit plan. J Managed Care Pharm 2002 Mar–Apr; 8(2): 124–31

    Google Scholar 

  98. Armour BS, Pitts MM, MacLean R, et al. The effect of explicit financial incentives on physician behavior. Arch Intern Med 2001 May 28; 161(10): 1261–6

    Article  PubMed  CAS  Google Scholar 

  99. McCombs JS, Liu G, Shi J, et al. The Kaiser Permanente/USC patient consultation study: change in use and cost of health care services. Am J Health Syst Pharm 1998 Dec 1; 55(23): 2485–99

    PubMed  CAS  Google Scholar 

  100. Gerber RA, Liu G, McCombs JS. Impact of pharmacist consultations provided to patients with diabetes on healthcare costs in a health maintenance organization. Am J Manag Care 1998 Jul; 4(7): 991–1000

    PubMed  CAS  Google Scholar 

  101. Ellis SL, Billups SJ, Malone DC, et al. Types of interventions made by clinical pharmacists in the IMPROVE study: impact of managed pharmaceutical care on resource utilization and outcomes in veteran’s affairs medical centers. Pharmacotherapy 2000 Apr; 20(4): 429–35

    Article  PubMed  CAS  Google Scholar 

  102. Blakey SA, Hixson-Wallace JA. Clinical and economic effects of pharmacy services in geriatric ambulatory clinics. Pharmacotherapy 2000 Oct; 20(10): 1198–203

    Article  PubMed  CAS  Google Scholar 

  103. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE Study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veteran’s Affairs Medical Centers. Pharmacotherapy 2000 Dec; 20(12): 1508–16

    Article  PubMed  CAS  Google Scholar 

  104. Soumerai SB. Adding value to appropriate drug use and prescription drug programs: presented at the Appropriate Drug Use and Prescription Drug Programs: adding value by improving quality. Workshop brief, 2001, Nov 5–7, Association for Health Research and Outcomes (AHRQ), User Liaison Program [online]. Available from URL: http://www.ahrq.gov/news/ulp/pharm/pharm8.htm [Accessed 2003 Oct 14]

Download references

Acknowledgments

This review was funded exclusively by the senior author. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Pharmacy Care Management, Henry Ford Health System, Bingham Farms, Michigan, USA

    Rachel Czubak, Jasmine Tucker &  Barbara J. Zarowitz Pharm.D. (Chief Clinical Officer, Vice President)

Authors
  1. Rachel Czubak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jasmine Tucker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara J. Zarowitz Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara J. Zarowitz Pharm.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czubak, R., Tucker, J. & Zarowitz, B.J. Optimizing Drug Prescribing in Managed Care Populations. Dis-Manage-Health-Outcomes 12, 147–167 (2004). https://doi.org/10.2165/00115677-200412030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200412030-00002

Keywords

Search

Navigation